At the 6-year mark, CheckMate 9LA reveals significant long-term survival benefits for metastatic non-small cell lung cancer patients using dual immunotherapy with nivolumab and ipilimumab. These data were featured in the 2025 Year in Review in Non-Small Cell Lung Cancer.
